

# Gary H Lyman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789224/publications.pdf>

Version: 2024-02-01

544  
papers

57,454  
citations

1301

109  
h-index

1158

229  
g-index

553  
all docs

553  
docs citations

553  
times ranked

41164  
citing authors

#	ARTICLE	IF	CITATIONS
1	Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library, 2022, 2022, CD003039.	2.8	85
2	Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Investigation, 2022, 40, 115-123.	1.3	20
3	Examining pain among non-Hispanic Black and non-Hispanic White patients with cancer visiting emergency departments: CONCERN (Comprehensive Oncologic Emergencies Research Network). Academic Emergency Medicine, 2022, 29, 364-368.	1.8	0
4	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 2022, 40, 17-25.	1.3	2
5	Use of Biosimilar Medications in Oncology. JCO Oncology Practice, 2022, 18, 177-186.	2.9	15
6	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	5.0	12
7	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. BMC Health Services Research, 2022, 22, 432.	2.2	1
8	Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. Advances in Therapy, 2022, 39, 2778-2795.	2.9	3
9	Palliative Care Needs and Clinical Outcomes of Patients with Advanced Cancer in the Emergency Department. Journal of Palliative Medicine, 2022, 25, 1115-1121.	1.1	2
10	Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies. JCO Oncology Practice, 2021, 17, e406-e415.	2.9	8
11	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 685-693.	1.6	66
12	Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leukemia and Lymphoma, 2021, 62, 1203-1210.	1.3	9
13	Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer, 2021, 29, 2179-2186.	2.2	22
14	Expenditures among young adults with acute lymphoblastic leukemia by site of care. Cancer, 2021, 127, 1901-1911.	4.1	4
15	Cancer pain management in the emergency department: a multicenter prospective observational trial of the Comprehensive Oncologic Emergencies Research Network (CONCERN). Supportive Care in Cancer, 2021, 29, 4543-4553.	2.2	19
16	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	5.2	431
17	Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer. Cancer Investigation, 2021, 39, 205-213.	1.3	17
18	Aligning Cancer Clinical Trials With Cancer Burden. JAMA Oncology, 2021, 7, 357.	7.1	5

#	ARTICLE	IF	CITATIONS
19	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. Cancer Investigation, 2021, 39, 1-6.	1.3	4
20	Medications in Single-Dose Vials and Implications of Discarded Injectable Drugs. JAMA - Journal of the American Medical Association, 2021, 325, 1507.	7.4	4
21	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 2037-2048.	1.6	51
22	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	5.4	39
23	Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. Expert Review of Anticancer Therapy, 2021, 21, 1145-1159.	2.4	5
24	Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era. Frontiers in Oncology, 2021, 11, 697908.	2.8	13
25	Opportunities and Challenges of Observational Studies and Randomized Controlled Trials for Evaluating the Therapeutic Efficacy of COVID-19 Convalescent Plasma. Cancer Investigation, 2021, 39, 449-456.	1.3	2
26	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
27	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Frontiers in Immunology, 2021, 12, 706186.	4.8	27
28	Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncology Practice, 2021, 17, e1235-e1245.	2.9	13
29	COVID-19 and Cancer. JAMA Oncology, 2021, 7, 1882.	7.1	42
30	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	5.2	10
31	Healthcare costs of patients with cancer stratified by Khorana score risk levels. Journal of Medical Economics, 2021, 24, 866-873.	2.1	1
32	Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer, 2021, 127, 1459-1468.	4.1	98
33	Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. Cancer Investigation, 2021, 39, 1-5.	1.3	7
34	Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 18-21.	4.9	32
35	Expenditures in Young Adults with Hodgkin Lymphoma: NCI-designated Comprehensive Cancer Centers vs. Other Sites. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0321.2021.	2.5	0
36	Observation Unit Use Among Patients with Cancer Following Emergency Department Visits: Results of a Multicenter Prospective Cohort from CONCERN. Academic Emergency Medicine, 2021, , .	1.8	4

#	ARTICLE	IF	CITATIONS
37	Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Supportive Care in Cancer, 2020, 28, 925-932.	2.2	38
38	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2020, 38, 496-520.	1.6	971
39	Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current Medical Research and Opinion, 2020, 36, 483-495.	1.9	14
40	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	4.1	70
41	The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Annals of Hematology, 2020, 99, 121-126.	1.8	16
42	Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. JAMA Oncology, 2020, 6, 1969.	7.1	8
43	Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 2782-2797.	1.6	201
44	Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. Journal of Geriatric Oncology, 2020, 11, 1309-1315.	1.0	2
45	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. Thrombosis Research, 2020, 191, S79-S84.	1.7	22
46	Crowdsourcing in Crisis: Rising to the Occasion. JCO Clinical Cancer Informatics, 2020, 4, 551-554.	2.1	8
47	Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Targeted Oncology, 2020, 15, 467-475.	3.6	11
48	Randomized Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative. Cancer Investigation, 2020, 38, 537-542.	1.3	7
49	COVID-19, Cancer, and Consequences: Where Are We Now?. Cancer Investigation, 2020, 38, 431-435.	1.3	6
50	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. Cancer Medicine, 2020, 9, 8062-8073.	2.8	23
51	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology, the, 2020, 7, e746-e755.	4.6	21
52	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Advances, 2020, 4, 4045-4051.	5.2	13
53	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Medical Research Methodology, 2020, 20, 113.	3.1	37
54	Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 152, 103005.	4.4	7

#	ARTICLE	IF	CITATIONS
55	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
56	Financial Toxicity, Financial Abuse, or Financial Torture: Let's Call It What It Is!. <i>Cancer Investigation</i> , 2020, 38, 139-142.	1.3	6
57	Crowdsourcing a crisis response for COVID-19 in oncology. <i>Nature Cancer</i> , 2020, 1, 473-476.	13.2	66
58	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	3.8	60
59	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020, 126, 1736-1748.	4.1	23
60	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
61	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 12-22.	4.9	70
62	Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study. <i>BMC Cancer</i> , 2019, 19, 792.	2.6	14
63	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151.	3.8	41
64	Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer. <i>Journal of Emergency Medicine</i> , 2019, 57, 354-361.	0.7	22
65	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2916-2946.	1.6	127
66	Rumors of the Death of Biosimilars Have Been Greatly Exaggerated. <i>Cancer Investigation</i> , 2019, 37, 325-326.	1.3	2
67	Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. <i>Thrombosis Research</i> , 2019, 180, 37-42.	1.7	15
68	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. <i>BMC Medical Research Methodology</i> , 2019, 19, 119.	3.1	26
69	Febrile Neutropenia: An Ounce of Prevention or a Pound of Cure. <i>Journal of Oncology Practice</i> , 2019, 15, 27-29.	2.5	5
70	Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments. <i>JAMA Network Open</i> , 2019, 2, e190979.	5.9	99
71	Biosimilars: what the oncologist should know. <i>Future Oncology</i> , 2019, 15, 1147-1165.	2.4	24
72	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	27.0	520

#	ARTICLE	IF	CITATIONS
73	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology, 2019, 3, 1-10.	3.0	7
74	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thrombosis Research, 2019, 173, 158-163.	1.7	228
75	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 840-847.	4.9	101
76	Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clinical Breast Cancer, 2018, 18, 380-386.	2.4	51
77	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. Clinical Lung Cancer, 2018, 19, e163-e169.	2.6	24
78	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist, 2018, 23, 247-255.	3.7	63
79	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. Blood Reviews, 2018, 32, 81-87.	5.7	41
80	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Supportive Care in Cancer, 2018, 26, 7-20.	2.2	51
81	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Annals of Surgical Oncology, 2018, 25, 356-377.	1.5	130
82	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline Summary. Journal of Oncology Practice, 2018, 14, 495-499.	2.5	37
83	Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. Journal of Oncology Practice, 2018, 14, e176-e185.	2.5	74
84	Reply to S.D. Lucio. Journal of Clinical Oncology, 2018, 36, 2127-2127.	1.6	0
85	Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. Journal of Oncology Practice, 2018, 14, e801-e814.	2.5	3
86	American Society of Clinical Oncology Statement: Biosimilars in Oncology. Journal of Clinical Oncology, 2018, 36, 1260-1265.	1.6	88
87	Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety. Journal of Clinical Oncology, 2018, 36, 1773-1776.	1.6	4
88	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2018, 14, 242-245.	2.5	10
89	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 399-413.	1.6	190
90	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology, 2018, 36, 2017-2023.	1.6	967

#	ARTICLE	IF	CITATIONS
91	Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. <i>Journal of Oncology Practice</i> , 2018, 14, e194-e200.	2.5	29
92	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	1.6	131
93	American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	8
94	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 2647-2655.	1.6	262
95	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 491-497.	4.9	11
96	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018, 378, 2036-2044.	27.0	56
97	Integrative omics to detect bacteremia in patients with febrile neutropenia. <i>PLoS ONE</i> , 2018, 13, e0197049.	2.5	10
98	Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. <i>Thrombosis Research</i> , 2018, 164, S112-S118.	1.7	114
99	Immune-related Adverse Events in Cancer Patients. <i>Academic Emergency Medicine</i> , 2018, 25, 819-827.	1.8	18
100	Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. <i>BMC Cancer</i> , 2018, 18, 44.	2.6	230
101	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018, 379, 694-695.	27.0	15
102	Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 699-708.e1.	1.2	24
103	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12
104	The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category. <i>Blood</i> , 2018, 132, 3798-3798.	1.4	1
105	Comparative analysis of multigene assays (MGA) effects on chemotherapy (CT) de-escalation for women with NO, ER+ early stage breast cancer (ESBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e12519-e12519.	1.6	3
106	Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018, 132, 3531-3531.	1.4	0
107	Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 33-42.	0.9	3
108	Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 39-52.	1.4	4



#	ARTICLE	IF	CITATIONS
109	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 196-198.	2.5	63
110	Chemotherapy Use at the End of Life in Uganda. <i>Journal of Global Oncology</i> , 2017, 3, 711-719.	0.5	6
111	Depression and Health Care Utilization at End-of-Life Among Older Adults with Non-Small Cell Lung Cancer (TH320D). <i>Journal of Pain and Symptom Management</i> , 2017, 53, 326-327.	1.2	0
112	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
113	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. <i>Cancer</i> , 2017, 123, 2506-2515.	4.1	7
114	Costs, Trends, and Related Factors in Treating Lung Cancer Patients in 67 Hospitals in Guangxi, China. <i>Cancer Investigation</i> , 2017, 35, 345-357.	1.3	5
115	Vascular Complications of Cancer and Cancer Therapy. , 2017, , 215-240.		0
116	The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. <i>Supportive Care in Cancer</i> , 2017, 25, 2619-2629.	2.2	45
117	Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. <i>Pharmacoeconomics</i> , 2017, 35, 425-438.	3.3	25
118	Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. <i>JAMA Oncology</i> , 2017, 3, 996.	7.1	134
119	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 561-564.	1.6	359
120	A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1543-1550.	4.9	19
121	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 461-470.	1.4	13
122	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. <i>JAMA Oncology</i> , 2017, 3, 374.	7.1	58
123	Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. <i>Supportive Care in Cancer</i> , 2017, 25, 439-447.	2.2	38
124	Predicting neutropenia risk in patients with cancer using electronic data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e-e.	4.4	16
125	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	3.4	53
126	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1520-1541.	4.9	104



#	ARTICLE	IF	CITATIONS
127	Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2017, 1, 1-13.	3.0	3
128	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. JNCI Cancer Spectrum, 2017, 1, pkx009.	2.9	6
129	American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. Journal of Oncology Practice, 2017, 13, 207-210.	2.5	32
130	Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2017, 35, 1845-1854.	1.6	87
131	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3240-3261.	1.6	454
132	Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology, 2017, 35, 1139-1139.	1.6	0
133	Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. Journal of Oncology Practice, 2017, 13, 7s-9s.	2.5	7
134	The role of chronic disease in the costs of potentially preventable emergency department use during treatment: A regional study.. Journal of Clinical Oncology, 2017, 35, 6505-6505.	1.6	1
135	Patterns in provider types and cost of surveillance testing in early-stage breast cancer patients: A regional study.. Journal of Clinical Oncology, 2017, 35, 6582-6582.	1.6	1
136	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. Journal of Clinical Oncology, 2017, 35, e18290-e18290.	1.6	1
137	Neutropenia. , 2017, , 3085-3088.		0
138	Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo).. Journal of Clinical Oncology, 2017, 35, 280-280.	1.6	0
139	Out of system (OOS) costs for oncology clinics treating patients with breast, colorectal, and non-small cell lung cancer in Washington state.. Journal of Clinical Oncology, 2017, 35, 5-5.	1.6	0
140	Systematic reviews and meta-analyses in geriatric oncology.. Journal of Clinical Oncology, 2017, 35, e21517-e21517.	1.6	0
141	Predictors of advanced imaging use during breast cancer surveillance.. Journal of Clinical Oncology, 2017, 35, e18337-e18337.	1.6	0
142	Abstract 2767: Consistency of standing orders for primary prophylactic CSF within a national network of community oncology practices: SWOG intergroup trial S1415CD. , 2017, , .		0
143	Issues on the Use of White Blood Cell Growth Factors in Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e528-e532.	3.8	3
144	Innovations in American Society of Clinical Oncology Practice Guideline Development. Journal of Clinical Oncology, 2016, 34, 3213-3220.	1.6	14

#	ARTICLE	IF	CITATIONS
145	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	1.9	18
146	Evaluation and Regulation of Oncology Drug Approval. <i>JAMA Oncology</i> , 2016, 2, 728.	7.1	4
147	Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2066.	1.6	17
148	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) â€“Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	1.6	112
149	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 43-73.	329.8	497
150	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239.	329.8	419
151	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3872-3879.	1.6	28
152	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	1.6	538
153	Biomarker Tests for Molecularly Targeted Therapies â€” The Key to Unlocking Precision Medicine. <i>New England Journal of Medicine</i> , 2016, 375, 4-6.	27.0	101
154	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867.	3.7	54
155	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-518.	1.6	0
156	Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 483-492.	2.4	13
157	Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology. <i>Genetics in Medicine</i> , 2016, 18, 780-787.	2.4	17
158	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-635.	1.6	651
159	Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs. <i>JAMA Oncology</i> , 2016, 2, 425.	7.1	19
160	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2016, 34, 381-386.	1.6	173
161	Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 283-290.	1.3	12
162	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016, 128, 1422-1422.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Incidence of bone metastases in U.S. patients with solid tumors.. Journal of Clinical Oncology, 2016, 34, e13099-e13099.	1.6	3
164	The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.. Journal of Clinical Oncology, 2016, 34, 78-78.	1.6	1
165	Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.. Journal of Clinical Oncology, 2016, 34, 32-32.	1.6	4
166	Value in cancer care: Regional initiative to improve care through data reporting and interventions.. Journal of Clinical Oncology, 2016, 34, 34-34.	1.6	0
167	Measuring adherence to a Choosing Wisely recommendation in a regional oncology clinic.. Journal of Clinical Oncology, 2016, 34, 196-196.	1.6	0
168	Regional initiative to use data transparency to improve cancer care.. Journal of Clinical Oncology, 2016, 34, 39-39.	1.6	0
169	HICOR IQ: Developing a regional oncology metric reporting platform.. Journal of Clinical Oncology, 2016, 34, 165-165.	1.6	0
170	Regional engagement to define, report, and use quality metrics to improve palliative care in oncology.. Journal of Clinical Oncology, 2016, 34, 282-282.	1.6	4
171	Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy.. Journal of Clinical Oncology, 2016, 34, 9078-9078.	1.6	1
172	Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).. Journal of Clinical Oncology, 2016, 34, 6568-6568.	1.6	0
173	End of life services for cancer patients: A population-based evaluation.. Journal of Clinical Oncology, 2016, 34, 6524-6524.	1.6	0
174	Health care utilization and costs at end of life among patients with leukemia or lymphoma in a regional cancer registry-insurance claims linked database.. Journal of Clinical Oncology, 2016, 34, 184-184.	1.6	0
175	Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology, 2015, 1, 158.	7.1	55
176	Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?. Cancer Medicine, 2015, 4, 1153-1160.	2.8	27
177	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood, 2015, 126, 2790-2797.	1.4	46
178	Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1383-1393.	4.9	89
179	Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 979-986.	4.9	17
180	Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e1-e7.	4.9	39

#	ARTICLE	IF	CITATIONS
181	Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. <i>Journal of Oncology Practice</i> , 2015, 11, 338-343.	2.5	27
182	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. <i>SpringerPlus</i> , 2015, 4, 396.	1.2	16
183	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	1.6	911
184	Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. <i>Journal of Oncology Practice</i> , 2015, 11, 47-54.	2.5	61
185	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	1.6	783
186	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3199-3212.	1.6	680
187	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	3.0	128
188	When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward. <i>Journal of Clinical Oncology</i> , 2015, 33, 1995-1997.	1.6	7
189	Appropriate Role for Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 232-234.	1.6	23
190	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2015, 11, e442-e444.	2.5	115
191	When is good, good enough? Methodological pragmatism for sustainable guideline development. <i>Implementation Science</i> , 2015, 10, 28.	6.9	15
192	Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 659-667.	2.5	13
193	Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. <i>JAMA Oncology</i> , 2015, 1, 1098.	7.1	49
194	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. <i>Genetics in Medicine</i> , 2015, 17, 63-67.	2.4	16
195	Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. <i>Blood</i> , 2015, 126, 427-427.	1.4	12
196	Evolving Healthcare Quality in Top Tertiary General Hospitals in China during the China Healthcare Reform (2010â€“2012) from the Perspective of Inpatient Mortality. <i>PLoS ONE</i> , 2015, 10, e0140568.	2.5	14
197	Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN. , 2015, , .		0
198	CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2079-TPS2079.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. <i>American Health and Drug Benefits</i> , 2015, 8, 273-82.	0.5	29
200	Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. <i>Journal of Medical Economics</i> , 2014, 17, 32-42.	2.1	26
201	Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. <i>Cancer Medicine</i> , 2014, 3, 434-444.	2.8	85
202	Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. <i>Supportive Care in Cancer</i> , 2014, 22, 3275-3285.	2.2	21
203	Imagine a world without cancer. <i>BMC Cancer</i> , 2014, 14, 186.	2.6	12
204	Reply to L.K. Griffeth et al and J.E. Battley et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2812-2813.	1.6	0
205	Reply to I.A. Voutsadakis et al and A. Goyal et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3902-3904.	1.6	6
206	Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 446-453.	1.4	9
207	Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 190-199.	4.4	230
208	Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 1502-1506.	1.6	167
209	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 1365-1383.	1.6	713
210	Biosimilars: A cure to the U.S. health care cost conundrum?. <i>Blood Reviews</i> , 2014, 28, 263-268.	5.7	22
211	Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need. <i>Internal and Emergency Medicine</i> , 2014, 9, 497-499.	2.0	9
212	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1840-1850.	1.6	486
213	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S122-S127.	1.7	44
214	Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 190-198.	0.9	69
215	Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure. <i>Annals of Internal Medicine</i> , 2014, 160, 672.	3.9	100
216	Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia. <i>Blood</i> , 2014, 124, 2601-2601.	1.4	4

#	ARTICLE	IF	CITATIONS
217	Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study.. Journal of Clinical Oncology, 2014, 32, 558-558.	1.6	3
218	Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study.. Journal of Clinical Oncology, 2014, 32, 532-532.	1.6	0
219	A national survey of breast cancer screening in rural America.. Journal of Clinical Oncology, 2014, 32, 6546-6546.	1.6	0
220	Regional initiative to define, collect, and report value metrics in cancer care.. Journal of Clinical Oncology, 2014, 32, 25-25.	1.6	0
221	Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen. Cancer, 2013, 119, 3703-3709.	4.1	9
222	Chemotherapy dosing in overweight and obese patients with cancer. Nature Reviews Clinical Oncology, 2013, 10, 451-459.	27.6	79
223	Update on the Role of Epothilones in Metastatic Breast Cancer. Current Breast Cancer Reports, 2013, 5, 51-56.	1.0	2
224	A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Research and Treatment, 2013, 139, 863-872.	2.5	39
225	Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Critical Reviews in Oncology/Hematology, 2013, 88, 1-18.	4.4	49
226	Multidisciplinary Care of Patients with Early-Stage Breast Cancer. Surgical Oncology Clinics of North America, 2013, 22, 299-317.	1.5	4
227	Counting the costs of cancer care. Lancet Oncology, The, 2013, 14, 1142-1143.	10.7	11
228	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 2189-2204.	1.6	717
229	Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. Journal of Geriatric Oncology, 2013, 4, 310-318.	1.0	20
230	Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecologic Oncology, 2013, 129, 74-80.	1.4	75
231	Appropriate chemotherapy dosing in obese patients with cancer. Nature Reviews Clinical Oncology, 2013, 10, 664-664.	27.6	5
232	Comparative Effectiveness Research in Oncology. Oncologist, 2013, 18, 752-759.	3.7	18
233	Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. Journal of the National Cancer Institute, 2013, 105, 929-936.	6.3	30
234	Reply to T.H. Oo. Journal of Clinical Oncology, 2013, 31, 4381-4382.	1.6	3



#	ARTICLE	IF	CITATIONS
235	The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Oncology</i> , 2013, 24, 2475-2484.	1.2	161
236	Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. <i>Genetics in Medicine</i> , 2013, 15, 203-211.	2.4	44
237	Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis. <i>Oncologist</i> , 2013, 18, 1321-1329.	3.7	161
238	American Society of Clinical Oncology 2013 Top Five List in Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 4362-4370.	1.6	126
239	Will Biosimilars Gain Momentum?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1291-1297.	4.9	18
240	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1266-1290.	4.9	53
241	Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival. <i>Blood</i> , 2013, 122, 3597-3597.	1.4	2
242	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e337-e345.	3.8	16
243	National survey of breast cancer screening in rural America.. <i>Journal of Clinical Oncology</i> , 2013, 31, 13-13.	1.6	3
244	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e337-e345.	3.8	9
245	Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3898-3899.	1.6	0
246	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 2912-2918.	1.6	301
247	Making Genuine Progress Against Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3448-3451.	1.6	13
248	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012, 8, e65-e66.	2.5	4
249	Comparative Effectiveness Research in Oncology: An Overview. <i>Journal of Clinical Oncology</i> , 2012, 30, 4181-4184.	1.6	50
250	Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?. <i>Journal of Clinical Oncology</i> , 2012, 30, 580-581.	1.6	15
251	Weight-Based Chemotherapy Dosing in Obese Patients With Cancer: Back to the Future. <i>Journal of Oncology Practice</i> , 2012, 8, e62-e64.	2.5	20
252	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012, 8, e59-e61.	2.5	33



#	ARTICLE	IF	CITATIONS
253	American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review—Based Consensus Methodology. <i>Journal of Clinical Oncology</i> , 2012, 30, 3136-3140.	1.6	146
254	Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer. <i>Chemotherapy</i> , 2012, 58, 8-18.	1.6	40
255	Epilogue: The Peril and the Promise of Comparative Effectiveness Research in Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 4282-4282.	1.6	3
256	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012, 142, 265-266.	0.8	3
257	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 1553-1561.	1.6	430
258	Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. <i>Pharmacoeconomics</i> , 2012, 30, 103-118.	3.3	9
259	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Annals of Surgical Oncology</i> , 2012, 19, 3313-3324.	1.5	101
260	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. <i>Genetics in Medicine</i> , 2012, 14, 633-642.	2.4	36
261	A Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients with T3, Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs. <i>Value in Health</i> , 2012, 15, 1014-1021.	0.3	21
262	Costs Associated with Febrile Neutropenia in the US. <i>Pharmacoeconomics</i> , 2012, 30, 809-823.	3.3	61
263	Pharmacoeconomics of the Myeloid Growth Factors. <i>Pharmacoeconomics</i> , 2012, 30, 497-511.	3.3	24
264	Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 532-540.	3.8	24
265	Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. <i>Cancer</i> , 2012, 118, 3377-3386.	4.1	933
266	Cost effectiveness of gene expression profiling for early stage breast cancer. <i>Cancer</i> , 2012, 118, 6298-6299.	4.1	4
267	Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 301-310.	2.5	54
268	Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 296-308.	4.4	21
269	Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 625-630.	1.4	28
270	Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors. , 2012, , 409-420.		1

#	ARTICLE	IF	CITATIONS
271	Current patterns of chemotherapy and supportive care for early-stage breast cancer (ESBC).. Journal of Clinical Oncology, 2012, 30, 1062-1062.	1.6	0
272	Prospective cohort study of chemotherapy-associated toxicity and supportive care in oncology practice.. Journal of Clinical Oncology, 2012, 30, 9135-9135.	1.6	0
273	The incidence of venous thromboembolism in cancer patients: a real-world analysis. Clinical Advances in Hematology and Oncology, 2012, 10, 40-2.	0.3	11
274	Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. Journal of Clinical Oncology, 2011, 29, 1757-1764.	1.6	197
275	Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy. Medical Care, 2011, 49, 649-657.	2.4	16
276	A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Current Opinion in Hematology, 2011, 18, 1-10.	2.5	6
277	Comparison of Demographic Characteristics, Surgical Resection Patterns, and Survival Outcomes for Veterans and Nonveterans with Non-small Cell Lung Cancer in the Pacific Northwest. Journal of Thoracic Oncology, 2011, 6, 1726-1732.	1.1	22
278	NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-22.	4.9	118
279	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 914-932.	4.9	25
280	Biosimilars: Are They Ready for Primetime in the United States?. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 934-943.	4.9	29
281	Systematic Review of 99mTc Human Serum Albumin and 99mTc Sulfur Colloid Studies of Sentinel Lymph Node Biopsy of Cutaneous Melanoma of the Head and Neck. Laryngoscope, 2011, 121, S106-S106.	2.0	0
282	Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Research and Treatment, 2011, 127, 511-520.	2.5	9
283	Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Research and Treatment, 2011, 130, 255-266.	2.5	15
284	Breast Cancer Screening with Mammography. Current Oncology Reports, 2011, 13, 63-70.	4.0	18
285	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 2011, 117, 1917-1927.	4.1	195
286	Venous thromboembolism in the patient with cancer. Cancer, 2011, 117, 1334-1349.	4.1	158
287	Reply to risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 2011, 117, 5246-5246.	4.1	0
288	Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy. Journal of the National Cancer Institute, 2011, 103, 910-913.	6.3	29

#	ARTICLE	IF	CITATIONS
289	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Oncology Practice, 2011, 7, 395-398.	2.5	52
290	Sentinel Node Biopsy for Head and Neck Melanoma. Otolaryngology - Head and Neck Surgery, 2011, 145, 375-382.	1.9	120
291	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta-Analysis. Journal of Clinical Oncology, 2011, 29, 1479-1487.	1.6	186
292	Reply to S. Hapani et al. Journal of Clinical Oncology, 2011, 29, 3490-3491.	1.6	1
293	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2011, 29, 4189-4198.	1.6	822
294	Commentary: Chemotherapy Dosing in Obese Patients With Cancer—The Need for Evidence-Based Clinical Practice Guidelines. Journal of Oncology Practice, 2011, 7, 17-18.	2.5	10
295	Commentary: Should Cost and Comparative Value of Treatments Be Considered in Clinical Practice Guidelines?. Journal of Oncology Practice, 2011, 7, 398-401.	2.5	6
296	Long-Term Outcomes of Myeloid Growth Factor Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 945-952.	4.9	13
297	Neutropenia. , 2011, , 2506-2509.		0
298	Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma. Blood, 2011, 118, 2670-2670.	1.4	3
299	Comparative effectiveness research and genomic personalized medicine. Personalized Medicine, 2010, 7, 223-227.	1.5	5
300	Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review. Journal of Clinical Oncology, 2010, 28, 2914-2924.	1.6	167
301	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment, 2010, 121, 771-776.	2.5	2
302	Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. Journal of Hematology and Oncology, 2010, 3, 27.	17.0	12
303	Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 2010, 116, 5555-5563.	4.1	202
304	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology/Hematology, 2010, 74, 203-210.	4.4	27
305	Economic Implications of 21-Gene Recurrence Score Assay: US Multicenter Experience. Journal of Clinical Oncology, 2010, 28, e382-e382.	1.6	8
306	Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. Cancer Treatment and Research, 2010, 157, 145-165.	0.5	16

#	ARTICLE	IF	CITATIONS
307	Reply to N. Lathia et al. Journal of Clinical Oncology, 2010, 28, e764-e764.	1.6	0
308	Breast Cancer Screening: Science, Society and Common Sense. Cancer Investigation, 2010, 28, 1-6.	1.3	5
309	How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. Journal of Oncology Practice, 2010, 6, 149-152.	2.5	34
310	A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer. Cancer Investigation, 2010, 28, 978-982.	1.3	65
311	Availability of Experimental Therapy Outside Oncology Randomized Clinical Trials in the United States. Journal of Clinical Oncology, 2010, 28, 5067-5073.	1.6	16
312	Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research, 2010, 126, 113-118.	1.7	115
313	Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines. Thrombosis Research, 2010, 125, S120-S127.	1.7	38
314	Anthracyclines in the Treatment of Early-Stage Breast Cancer: Ally or Adversary?. Cancer Investigation, 2010, 28, 217-219.	1.3	2
315	Introduction to the Hematopoietic Growth Factors. Cancer Treatment and Research, 2010, 157, 3-10.	0.5	2
316	Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome. Cancer Treatment and Research, 2010, 157, 167-178.	0.5	2
317	The Myeloid Growth Factors. Cancer Treatment and Research, 2010, 157, 109-125.	0.5	1
318	The Economics of the Hematopoietic Growth Factors. Cancer Treatment and Research, 2010, 157, 403-418.	0.5	0
319	Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer. Cancer Investigation, 2009, 27, 885-890.	1.3	6
320	Preventing Venous Thromboembolism in Cancer Patients: Can We Do Better?. Journal of Oncology Practice, 2009, 5, 165-166.	2.5	1
321	Comparative Effectiveness Research in Oncology: The Need for Clarity, Transparency and Vision. Cancer Investigation, 2009, 27, 593-597.	1.3	14
322	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. Cancer Investigation, 2009, 27, 953-959.	1.3	19
323	Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826.	1.6	149
324	Does Treatment Intensity Matter in Superficial Bladder Cancer? Consensus, Clinical Practice, and Confounding. Journal of the National Cancer Institute, 2009, 101, 543-545.	6.3	3

#	ARTICLE	IF	CITATIONS
325	Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics, 2009, 31, 1092-1104.	2.5	62
326	Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?. Cancer, 2009, 115, 2660-2670.	4.1	73
327	Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer, 2009, 115, 5319-5328.	4.1	39
328	Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer, 2009, 115, 5637-5650.	4.1	31
329	Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy. Value in Health, 2009, 12, 217-225.	0.3	46
330	Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion, 2009, 25, 401-411.	1.9	58
331	Cancer and Thrombosis: Back to the Future<i>Renewed Interest in an Old Problem</i>. Cancer Investigation, 2009, 27, 472-473.	1.3	8
332	Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. Journal of Clinical Oncology, 2009, 27, 4919-4926.	1.6	162
333	Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 99-108.	4.9	265
334	Breast Cancer Screening and Diagnosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 1060-1096.	4.9	317
335	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 64-83.	4.9	96
336	Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Blood, 2009, 114, 490-490.	1.4	12
337	Impact of Decision-Support On Clinicians' Assessment of Febrile Neutropenia Risk.. Blood, 2009, 114, 1409-1409.	1.4	0
338	Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. Cancer, 2008, 113, 224-224.	4.1	1
339	Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2008, 72, 24-33.	0.8	116
340	Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy. Value in Health, 2008, 11, 172-179.	0.3	70
341	Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Human Pathology, 2008, 39, 386-392.	2.0	61
342	Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. Archives of Internal Medicine, 2008, 168, 2377.	3.8	304

#	ARTICLE	IF	CITATIONS
343	Caring for the Elderly Cancer Patient: Training the Next Generation of Oncologists. Journal of Oncology Practice, 2008, 4, 193-194.	2.5	2
344	Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 1574.	7.4	89
345	Recommendations on the Use of <sup>18</sup> F-FDG PET in Oncology. Journal of Nuclear Medicine, 2008, 49, 480-508.	5.0	978
346	Impact of Disease Risk on Efficacy of Matched Related Bone Marrow Transplantation for Pediatric Acute Myeloid Leukemia: The Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 5797-5801.	1.6	100
347	American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges. Journal of Clinical Oncology, 2008, 26, 4022-4026.	1.6	49
348	ASCO Clinical Practice Guidelines: Past, Present and Future. Journal of Oncology Practice, 2008, 4, 236-237.	2.5	4
349	Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008, 111, 4902-4907.	1.4	1,682
350	Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 109-118.	4.9	192
351	Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern. Journal of Oncology Practice, 2008, 4, 114-115.	2.5	8
352	The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 942-953.	4.9	42
353	Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia. , 2008, , 509-530.		1
354	Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. Blood, 2008, 112, 172-172.	1.4	9
355	Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome. Blood, 2008, 112, 2390-2390.	1.4	11
356	Risk Prediction of Chemotherapy-Associated Toxicity in Patients Receiving Cancer Chemotherapy. Translational Medicine Series, 2008, , 1-23.	0.0	0
357	Neutropenia and Its Complications. Translational Medicine Series, 2008, , 1-19.	0.0	0
358	Optimal cancer care across the spectrum of life and disease. American Journal of Managed Care, 2008, 14, 262-4.	1.1	0
359	Variation in the cost of medications for the treatment of colorectal cancer. American Journal of Managed Care, 2008, 14, 717-25.	1.1	29
360	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. Translational Medicine Series, 2007, , 147-158.	0.0	0

#	ARTICLE	IF	CITATIONS
361	Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 187-188.	2.5	1
362	Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 277-284.	1.6	111
363	Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens. <i>Journal of Clinical Oncology</i> , 2007, 25, 2522-2527.	1.6	133
364	ASCO Clinical Practice Guidelines and Beyond. <i>Journal of Oncology Practice</i> , 2007, 3, 330-331.	2.5	4
365	Economics of Cancer Care. <i>Journal of Oncology Practice</i> , 2007, 3, 113-114.	2.5	11
366	Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 217-228.	4.9	21
367	Granulocyte colony-stimulating factors: finding the right indication. <i>Current Opinion in Oncology</i> , 2007, 19, 299-307.	2.4	24
368	Ductal carcinoma in situ: a review of recent advances. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 63-67.	2.0	18
369	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	1.6	875
370	Agents under investigation for the treatment and prevention of neutropenia. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1831-1840.	4.1	7
371	Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia. <i>Pharmacoeconomics</i> , 2007, 25, 343-351.	3.3	26
372	Advances in Cancer Investigation. <i>Cancer Investigation</i> , 2007, 25, 515-516.	1.3	0
373	Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2007, 25, 3158-3167.	1.6	639
374	Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2007, 23, 2283-2295.	1.9	150
375	Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. <i>Cancer</i> , 2007, 109, 1011-1018.	4.1	178
376	A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. <i>Cancer</i> , 2007, 110, 1149-1161.	4.1	198
377	Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. <i>Cancer</i> , 2007, 110, 1611-1620.	4.1	119
378	Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. <i>Cancer</i> , 2007, 110, 2339-2346.	4.1	662



#	ARTICLE	IF	CITATIONS
379	The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. <i>Transfusion</i> , 2007, 47, 573-581.	1.6	97
380	Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 632-634.	3.8	1,309
381	A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. <i>Blood</i> , 2007, 110, 372-372.	1.4	2
382	Cost-Effectiveness of Primary Prophylaxis with Pegfilgrastim Versus Filgrastim in Non-Hodgkinâ€™s Lymphoma Patients Receiving CHOP-21.. <i>Blood</i> , 2007, 110, 5166-5166.	1.4	1
383	Myeloid Growth Factors Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 188.	4.9	60
384	Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years. <i>Annals of Internal Medicine</i> , 2007, 147, 882.	3.9	1
385	Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007, , 137-146.	0.0	0
386	Venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1029-1033.	1.3	80
387	Screening mammography at 40â€“49 years: regret or no regret?. <i>Lancet, The</i> , 2006, 368, 2035-2037.	13.7	134
388	Gene Expression Profile Assays as Predictors of Recurrence-Free Survival in Early-Stage Breast Cancer: A Metaanalysis. <i>Clinical Breast Cancer</i> , 2006, 7, 372-379.	2.4	26
389	Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2006, 32, 289-303.	7.7	53
390	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2006, 24, 3187-3205.	1.6	1,530
391	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 255-262.	2.5	129
392	Risks and Consequences of Chemotherapy-Induced Neutropenia. <i>Clinical Cornerstone</i> , 2006, 8, S12-S18.	0.7	33
393	Lymphatic mapping and sentinel lymph node biopsy in earlyâ€“stage breast carcinoma. <i>Cancer</i> , 2006, 106, 4-16.	4.1	778
394	Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia?. <i>Cancer</i> , 2006, 106, 223-233.	4.1	44
395	Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. <i>Cancer</i> , 2006, 106, 2258-2266.	4.1	983
396	Burden of Pancreatic Cancer and Disease Progression: Economic Analysis in the US. <i>Oncology</i> , 2006, 70, 71-80.	1.9	22

#	ARTICLE	IF	CITATIONS
397	Thromboembolism in Hospitalized Neutropenic Cancer Patients. Journal of Clinical Oncology, 2006, 24, 484-490.	1.6	424
398	Withholding Antibiotics From Patients With Febrile Neutropenia. Journal of Clinical Oncology, 2006, 24, 1221-1222.	1.6	5
399	Pegfilgrastim Provides Effective Primary Prophylaxis Against Febrile Neutropenia in Patients with NHL Undergoing Chemotherapy: Initial Results from an Integrated Analysis - The Neulasta Versus Current Neutropenia Management Practice (Neucup) Project.. Blood, 2006, 108, 1150-1150.	1.4	1
400	Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.. Blood, 2006, 108, 460-460.	1.4	2
401	Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. Oncology, 2006, 20, 16-20.	0.5	1
402	Chemotherapy dose intensity and quality cancer care. Oncology, 2006, 20, 16-25.	0.5	42
403	Hemopoiesis and Aging. , 2005, 124, 109-134.		30
404	Time is Money for Both the Healthy and the Sick. Medical Care, 2005, 43, 637-639.	2.4	9
405	Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 557-571.	4.9	88
406	The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. Value in Health, 2005, 8, 149-156.	0.3	61
407	Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy. Value in Health, 2005, 8, 47-52.	0.3	26
408	The strengths and limitations of meta-analyses based on aggregate data. BMC Medical Research Methodology, 2005, 5, 14.	3.1	194
409	Use of re-randomized data in meta-analysis. BMC Medical Research Methodology, 2005, 5, 17.	3.1	15
410	Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 2005, 104, 2822-2829.	4.1	475
411	Length of Stay and Mortality Associated With Febrile Neutropenia Among Children With Cancer. Journal of Clinical Oncology, 2005, 23, 7958-7966.	1.6	123
412	Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. Archives of Internal Medicine, 2005, 165, 1267.	3.8	238
413	Risk Models for Predicting Chemotherapy-Induced Neutropenia. Oncologist, 2005, 10, 427-437.	3.7	275
414	Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opinion on Biological Therapy, 2005, 5, 1635-1646.	3.1	38

#	ARTICLE	IF	CITATIONS
415	A Primer in Prognostic and Predictive Models: Development and Validation of Neutropenia Risk Models. Supportive Cancer Therapy, 2005, 2, 168-175.	0.3	6
416	Moving Beyond Febrile Neutropenia. Supportive Cancer Therapy, 2005, 2, 95-97.	0.3	2
417	The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs. Pharmacoeconomics, 2005, 23, 183-192.	3.3	25
418	Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Oncology, 2005, 23, 4198-4214.	1.6	273
419	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7703-7720.	1.6	1,674
420	The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treatment Reviews, 2005, 31, 628-639.	7.7	10
421	Up-Front Therapy for Multiple Myeloma: A Survey of Practice Patterns in the USA.. Blood, 2005, 106, 5172-5172.	1.4	1
422	Myeloid Growth Factors Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 540.	4.9	29
423	A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.. Blood, 2005, 106, 3328-3328.	1.4	0
424	A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.. Blood, 2005, 106, 754-754.	1.4	0
425	Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. American Journal of Managed Care, 2005, 11, 313-24.	1.1	174
426	The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapy, 2004, 4, 1897-1910.	3.1	30
427	Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. Journal of Clinical Oncology, 2004, 22, 4302-4311.	1.6	285
428	Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony-Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy. Pharmacotherapy, 2004, 24, 488-494.	2.6	41
429	A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2004, 85, 143-150.	2.5	14
430	Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Supportive Care in Cancer, 2004, 12, 543-9.	2.2	129
431	Chemotherapy-induced neutropenia. Cancer, 2004, 100, 228-237.	4.1	725
432	Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature. Supportive Cancer Therapy, 2004, 2, 34-41.	0.3	16

#	ARTICLE	IF	CITATIONS
433	Prophylactic Pegfilgrastim Significantly Reduces Febrile Neutropenia During Moderately Myelosuppressive Chemotherapy. Supportive Cancer Therapy, 2004, 1, 207-209.	0.3	1
434	Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the united states and other countries. American Journal of Medicine, 2004, 116, 28-34.	1.5	18
435	Economics of Hematopoietic Growth Factors. , 2004, , 409-443.		5
436	First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.. Blood, 2004, 104, 2210-2210.	1.4	14
437	Gene Expression Profile Signatures to Predict Survival in Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Early Results.. Blood, 2004, 104, 2274-2274.	1.4	2
438	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkinâ€™s Lymphoma.. Blood, 2004, 104, 4542-4542.	1.4	2
439	Thromboembolism in Hospitalized Neutropenic Cancer Patients.. Blood, 2004, 104, 2199-2199.	1.4	0
440	Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature.. Blood, 2004, 104, 3714-3714.	1.4	0
441	Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.. Blood, 2004, 104, 4599-4599.	1.4	0
442	Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials.. Blood, 2004, 104, 2211-2211.	1.4	1
443	Balancing the benefits and costs of colony-stimulating factors: a current perspective. Seminars in Oncology, 2003, 30, 10-17.	2.2	29
444	Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer, 2003, 98, 2402-2409.	4.1	162
445	The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nursing, 2003, 2, 2.	2.5	18
446	Evidence-based oncology in cancer treatment reviews. Cancer Treatment Reviews, 2003, 29, 45-50.	7.7	3
447	Epidemiology of Febrile Neutropenia. Supportive Cancer Therapy, 2003, 1, 23-35.	0.3	92
448	Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. Journal of Clinical Oncology, 2003, 21, 4524-4531.	1.6	416
449	Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy. Leukemia and Lymphoma, 2003, 44, 2069-2076.	1.3	199
450	Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 440-454.	4.9	82

#	ARTICLE	IF	CITATIONS
451	Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients. <i>Cancer Control</i> , 2003, 10, 487-499.	1.8	47
452	Cost effectiveness of myeloid growth factors in cancer chemotherapy. <i>Psychophysiology</i> , 2003, 2, 471-9.	1.1	6
453	Risk assessment in oncology clinical practice. From risk factors to risk models. <i>Oncology</i> , 2003, 17, 8-13.	0.5	16
454	G-CSF as prophylaxis of febrile neutropenia in SCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1273-1281.	1.8	24
455	Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. <i>Current Opinion in Hematology</i> , 2002, 9, 207-214.	2.5	44
456	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. <i>American Journal of Medicine</i> , 2002, 112, 406-411.	1.5	216
457	Overlooking patient outcomes in a meta-analysis of trials of granulocyte colon-stimulating factor. <i>American Journal of Medicine</i> , 2002, 113, 766-768.	1.5	0
458	Filgrastim in Patients with Neutropenia. <i>Drugs</i> , 2002, 62, 65-78.	10.9	46
459	Exercise Prescription. <i>Annals of Internal Medicine</i> , 2002, 136, 564.	3.9	0
460	Patients Aged ≥ 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 1583-1585.	1.6	73
461	Hematopoietic growth factors in the older cancer patient. <i>Current Opinion in Hematology</i> , 2001, 8, 170-187.	2.5	54
462	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	1.6	2,394
463	Economic analysis of randomized, controlled trials. <i>Current Oncology Reports</i> , 2001, 3, 396-403.	4.0	8
464	Understanding economic analyses. <i>Evidence-based Oncology</i> , 2001, 2, 2-5.	0.1	9
465	Cancer in the Elderly. <i>Annals of Internal Medicine</i> , 2001, 134, 800.	3.9	0
466	Clinical Relevance of Molecular Staging for Melanoma. <i>Annals of Surgery</i> , 2000, 231, 795-803.	4.2	106
467	Evidentiary challenges to evidence-based medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 99-109.	1.8	40
468	Impact of Hot Flashes on Quality of Life Among Postmenopausal Women Being Treated for Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 2000, 19, 436-445.	1.2	107

#	ARTICLE	IF	CITATIONS
469	Understanding treatment benefits and harms. Evidence-based Oncology, 2000, 1, 66-68.	0.1	3
470	A Predictive Model for Neutropenia Associated with Cancer Chemotherapy. Pharmacotherapy, 2000, 20, 104S-111S.	2.6	26
471	Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2000, 62, 141-150.	2.5	139
472	Hemopoietic Reserve in the Older Cancer Patient: Clinical and Economic Considerations. Cancer Control, 2000, 7, 539-547.	1.8	77
473	What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?. Journal of Clinical Oncology, 2000, 18, 1709-1717.	1.6	203
474	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients with Breast Cancer. Annual Review of Medicine, 2000, 51, 525-542.	12.2	87
475	The uncertainty principle and industry-sponsored research. Lancet, The, 2000, 356, 635-638.	13.7	442
476	Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trialâ€¦Participants of the second Randomized Intervention Treatment of Angina (RITA-2) trial are listed in the Appendix.. Journal of the American College of Cardiology, 2000, 35, 907-914.	2.8	158
477	Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2000, , CD003039.		19
478	Fatigue in Women Receiving Adjuvant Chemotherapy for Breast Cancer. Journal of Pain and Symptom Management, 1999, 18, 233-242.	1.2	311
479	Update of the economic analyses of the use of the colony-stimulating factors. Current Opinion in Hematology, 1999, 6, 145.	2.5	29
480	Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Research and Treatment, 1998, 52, 289-303.	2.5	239
481	Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Annals of Surgical Oncology, 1998, 5, 376-383.	1.5	15
482	Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Annals of Surgical Oncology, 1998, 5, 522-528.	1.5	64
483	Molecular Staging of Malignant Melanoma. JAMA - Journal of the American Medical Association, 1998, 280, 1410.	7.4	341
484	Economie impact of granulopoiesis stimulating agents on the management of febrile neutropenia. Current Opinion in Oncology, 1998, 10, 291-296.	2.4	22
485	Comorbidity and functional status are independent in older cancer patients.. Journal of Clinical Oncology, 1998, 16, 1582-1587.	1.6	930
486	Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.. Journal of Clinical Oncology, 1998, 16, 1689-1696.	1.6	431

#	ARTICLE	IF	CITATIONS
487	Cancer Care in the Elderly: Cost and Quality-of-Life Considerations. Cancer Control, 1998, 5, 347-354.	1.8	19
488	Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients With Breast Cancer. Annals of Surgery, 1998, 227, 645-653.	4.2	557
489	Sentinel Lymph Node Biopsy in Melanoma of the Head and Neck. Plastic and Reconstructive Surgery, 1997, 100, 591-594.	1.4	147
490	Cancer in the Elderly: Epidemiologic and Clinical Implications. Clinics in Geriatric Medicine, 1997, 13, 1-14.	2.6	44
491	The Role of Selective Lymphadenectomy in Breast Cancer. Cancer Control, 1997, 4, 211-219.	1.8	13
492	Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival. Cancer Control, 1997, 4, 335-341.	1.8	7
493	Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcome. Annals of Surgical Oncology, 1997, 4, 644-649.	1.5	41
494	Bilaterality and recurrence rates for lobular breast cancer: Considerations for treatment. Annals of Surgical Oncology, 1997, 4, 198-202.	1.5	40
495	Importance of race on breast cancer survival. Annals of Surgical Oncology, 1997, 4, 80-87.	1.5	46
496	Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study. Cancer Control, 1996, 3, 1-4.	1.8	22
497	Evaluation of new putative tumor markers for melanoma. Annals of Surgical Oncology, 1996, 3, 558-563.	1.5	55
498	Intraoperative Radiolymphoscintigraphy Improves Sentinel Lymph Node Identification for Patients with Melanoma. Annals of Surgery, 1996, 223, 217-224.	4.2	473
499	Timing of weight gain and breast cancer risk. Cancer, 1995, 76, 243-249.	4.1	60
500	The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer, 1995, 76, 1634-1642.	4.1	112
501	Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. Clinical Infectious Diseases, 1994, 18, S189-S196.	5.8	7
502	Age as a prognostic factor in the malignant melanoma population. Annals of Surgical Oncology, 1994, 1, 487-494.	1.5	121
503	The effect of changing disease risk on clinical reasoning. Journal of General Internal Medicine, 1994, 9, 488-495.	2.6	37
504	The Orderly Progression of Melanoma Nodal Metastases. Annals of Surgery, 1994, 220, 759-767.	4.2	674



#	ARTICLE	IF	CITATIONS
505	Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. <i>Cancer</i> , 1993, 71, 2764-2768.	4.1	10
506	Overestimation of test effects in clinical judgment. <i>Journal of Cancer Education</i> , 1993, 8, 297-307.	1.3	37
507	A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 1992, 10, 257-263.	1.6	570
508	Advances in current cancer treatment: An overview. <i>Hematological Oncology</i> , 1992, 10, 3-6.	1.7	1
509	Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. <i>Hematological Oncology</i> , 1992, 10, 61-74.	1.7	8
510	RISK FACTORS FOR CANCER. Primary Care - Clinics in Office Practice, 1992, 19, 465-479.	1.6	16
511	Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration. <i>Gynecologic Oncology</i> , 1991, 43, 265-269.	1.4	13
512	Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1991, 325, 164-170.	27.0	1,342
513	The Effect of Duration of Intervention and Locus of Control on Dietary Change. <i>American Journal of Preventive Medicine</i> , 1991, 7, 341-347.	3.0	13
514	Breast Cancer of the Older Woman: An Annotated Review. <i>Journal of the American Geriatrics Society</i> , 1991, 39, 1113-1123.	2.6	16
515	A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. <i>Cancer</i> , 1991, 67, 245-249.	4.1	20
516	Obesity and body fat distribution and breast cancer prognosis. <i>Cancer</i> , 1991, 67, 523-528.	4.1	67
517	Obesity, body fat distribution, and sex hormones in breast cancer patients. <i>Cancer</i> , 1991, 67, 2215-2218.	4.1	61
518	Estimate of breast cancer risk reduction with weight loss. <i>Cancer</i> , 1991, 67, 2622-2625.	4.1	24
519	Serum cholesterol reduction with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 1990, 17, 3-7.	2.5	32
520	Abdominal Obesity and Breast Cancer Risk. <i>Annals of Internal Medicine</i> , 1990, 112, 182.	3.9	164
521	The value of current nutrition information. <i>Preventive Medicine</i> , 1990, 19, 45-53.	3.4	28
522	Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. <i>In Vitro Cellular &amp; Developmental Biology</i> , 1989, 25, 297-302.	1.0	46

#	ARTICLE	IF	CITATIONS
523	Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. <i>Gynecologic Oncology</i> , 1989, 35, 75-77.	1.4	22
524	Relation of results of exercise stress tests in young women to phases of the menstrual cycle. <i>American Journal of Cardiology</i> , 1988, 61, 197-199.	1.6	42
525	Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. <i>Gynecologic Oncology</i> , 1988, 29, 32-36.	1.4	13
526	Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 1028-1032.	7.1	361
527	LUNG CANCER IN FLORIDA. <i>American Journal of Epidemiology</i> , 1988, 128, 78-84.	3.4	7
528	Cigarette smoking and the, risk of female reproductive cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1987, 157, 35-40.	1.3	80
529	Peritoneal cytology and invasive carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1986, 24, 331-336.	1.4	17
530	Digitalis Use in a Retirement Community. <i>Journal of the American Geriatrics Society</i> , 1986, 34, 504-506.	2.6	4
531	Leukemia and Radium Groundwater Contamination-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1986, 255, 902.	7.4	0
532	Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. <i>Head &amp; Neck</i> , 1986, 9, 104-110.	0.3	82
533	Factors affecting the incidence of infectious morbidity after radical hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 1985, 152, 817-821.	1.3	33
534	High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia A phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 361-364.	1.3	4
535	Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. <i>American Journal of Medicine</i> , 1981, 70, 1222-1229.	1.5	38
536	The Use of Lithium Carbonate to Reduce Infection and Leukopenia during Systemic Chemotherapy. <i>New England Journal of Medicine</i> , 1980, 302, 257-260.	27.0	114
537	The Effect of Lithium Carbonate Administration in Patients with Advanced Small Cell Bronchogenic Carcinoma Receiving Combination Chemotherapy and Radiotherapy. <i>Advances in Experimental Medicine and Biology</i> , 1980, 127, 207-229.	1.6	4
538	Fibrinogen kinetics in patients with neoplastic disease. <i>Cancer</i> , 1978, 41, 1113-1122.	4.1	47
539	Combination Chemotherapy and Radiation Therapy of Undifferentiated Small Cell Bronchogenic Carcinoma. <i>Southern Medical Journal</i> , 1978, 71, 519-524.	0.7	11
540	Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy. <i>American Journal of Hematology</i> , 1977, 3, 209-218.	4.1	62

#	ARTICLE	IF	CITATIONS
541	Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of friend leukemic cell differentiation. Biochimica Et Biophysica Acta - Biomembranes, 1976, 448, 460-473.	2.6	66
542	Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation. Nature, 1976, 262, 360-363.	27.8	221
543	The myeloid growth factors in older adults with cancer. , 0, , 323-337.		0
544	Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. Cancer Investigation, 0, , 1-9.	1.3	0